Cullinan Oncology Revenue and Competitors
Estimated Revenue & Valuation
- Cullinan Oncology's estimated annual revenue is currently $18.9M per year.
- Cullinan Oncology's estimated revenue per employee is $146,822
- Cullinan Oncology's total funding is $379.7M.
- Cullinan Oncology's current valuation is $598M. (January 2022)
Employee Data
- Cullinan Oncology has 129 Employees.
- Cullinan Oncology grew their employee count by 24% last year.
Cullinan Oncology's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
Cullinan Oncology Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Cullinan Oncology?
Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
keywords:N/A
$379.7M
Total Funding
129
Number of Employees
$18.9M
Revenue (est)
24%
Employee Growth %
$598M
Valuation
N/A
Accelerator
Cullinan Oncology News
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) a biopharmaceutical company focused...
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple...
Cullinan Oncology is a biopharmaceutical company that is developing a diversified pipeline of targeted therapeutic candidates across multiple...
Cullinan Oncology, LLC announced that it has issued 66,599,045 series C preferred stock at a price of $1.97 per share for gross proceeds of $131,200,119.65 on December 17, 2020. The series C round of funding was led by Foresite Capital Management, LLC. The transaction included participation from ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cullinan Oncology, LLC, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the closing of an oversubscribed $131.2 millio ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $34.8M | 129 | -3% | N/A |
#2 | $27.1M | 129 | 54% | N/A |
#3 | $35.1M | 130 | 8% | N/A |
#4 | $28.6M | 130 | 20% | N/A |
#5 | $13.3M | 130 | -1% | N/A |